Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.

Trenkwalder C, Beneš H, Grote L, García-Borreguero D, Högl B, Hopp M, Bosse B, Oksche A, Reimer K, Winkelmann J, Allen RP, Kohnen R, RELOXYN Study Group

Open source

DOI
10.1016/s1474-4422(13)70239-4
Published
2013 Dec
Container
The Lancet. Neurology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1474-4422-13-70239-4,
  title = {Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.},
  author = {Trenkwalder C and Beneš H and Grote L and García-Borreguero D and Högl B and Hopp M and Bosse B and Oksche A and Reimer K and Winkelmann J and Allen RP and Kohnen R and RELOXYN Study Group},
  year = {2013},
  journal = {The Lancet. Neurology},
  doi = {10.1016/s1474-4422(13)70239-4},
  url = {https://doi.org/10.1016/s1474-4422(13)70239-4}
}

RIS

TY  - JOUR
TI  - Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
AU  - Trenkwalder C
AU  - Beneš H
AU  - Grote L
AU  - García-Borreguero D
AU  - Högl B
AU  - Hopp M
AU  - Bosse B
AU  - Oksche A
AU  - Reimer K
AU  - Winkelmann J
AU  - Allen RP
AU  - Kohnen R
AU  - RELOXYN Study Group
PY  - 2013
JO  - The Lancet. Neurology
DO  - 10.1016/s1474-4422(13)70239-4
UR  - https://doi.org/10.1016/s1474-4422(13)70239-4
ER  - 

APA

C, T., H, B., L, G., D, G., B, H., M, H., B, B., A, O., K, R., J, W., RP, A., R, K., & Group, R. S. (2013). Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(13)70239-4

Source records